Who Will Win the Hepatitis C Market?
Ketan Desai submits:The recent hoopla surrounding Pharmasset (VRUS), as well as the excitement regarding two NDAs for hepatitis C, made me take a closer look at this disease and what is coming down the pipeline. Hepatitis C virus (HCV), along with alcoholism, is one of the most important causes of chronic liver disease in the United States. Sixty to 70 percent of chronic hepatitis, and up to 50 percent of cirrhosis, end-stage liver disease, and liver cancer are caused by the virus. It is estimated that 4.1 million Americans have antibody to HCV (anti-HCV), and 1.2 million have active disease. Approximately three quarters of those infected develop chronic infection. The disease is responsible for about 10,000 deaths a year in the US alone. More details can be found at the NIH NIDDK website. The present standard of care is a combination therapy of interferon alpha and ribavirin for 24 – 48 weeks.Complete Story »